M.D. Anderson Cancer Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, M.D. Anderson Cancer Center sits in the top decile of US sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count).

2,692 total trials 549 currently recruiting 1201 completed early-phase tilt top decile by trial count

M.D. Anderson Cancer Center: 2,692 sponsored US clinical trials, 549 recruiting.

M.D. Anderson Cancer Center sponsors 2,692 registered US clinical trials on ClinicalTrials.gov, 549 of them currently recruiting, and 1,201 completed. 124 of these trials are in Phase 3-4 (later-stage) and 1,719 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hematopoietic and Lymphoid Cell Neoplasm, with 44 trials.

Top-decile sponsor footprint

M.D. Anderson Cancer Center ranks in the top decile of sponsors by registered trial count (#3 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

2,692 total, page 17 of 54

ACTIVE NOT RECRUITING Phase 1

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

NCT03025256
ACTIVE NOT RECRUITING Phase 2

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

NCT03449108
ACTIVE NOT RECRUITING NA

Use of a Smartphone Mobile Application (App) to Enhance Smoking Cessation Treatment

NCT03519451
ACTIVE NOT RECRUITING

A Prospective Study of Performing MRI Simulation in Treatment Position in Spinal Stereotactic Body Radiation Therapy

NCT05155423
ACTIVE NOT RECRUITING Phase 2

Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy

NCT03412396
ACTIVE NOT RECRUITING Phase 2

Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease

NCT03441061
ACTIVE NOT RECRUITING Phase 2

Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia

NCT03147612
ACTIVE NOT RECRUITING Phase 1

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

NCT03283917
ACTIVE NOT RECRUITING Phase 1

Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced

NCT03225664
ACTIVE NOT RECRUITING NA

Watchful Living in Improving Quality of Life in Participants With Localized Prostate Cancer on Active Surveillance and Their Partners

NCT03575832
ACTIVE NOT RECRUITING Phase 2

Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study

NCT03410043
ACTIVE NOT RECRUITING Phase 2

Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer

NCT03224000
ACTIVE NOT RECRUITING Phase 3

Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

NCT03391869
ACTIVE NOT RECRUITING Phase 2

Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer

NCT03087071
ACTIVE NOT RECRUITING NA

Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants

NCT03546972
ACTIVE NOT RECRUITING NA

An Early Stress-Reduction Intervention in Patients With Newly Diagnosed Breast Cancer

NCT03429907
ACTIVE NOT RECRUITING Phase 2

Dexamethasone in Controlling Dyspnea in Patients With Cancer

NCT03367156
ACTIVE NOT RECRUITING NA

PREVENT: PeRomEter Visualization to ENd Treatment-related Lymphedema

NCT05056207
ACTIVE NOT RECRUITING Phase 2

Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer

NCT03359954
ACTIVE NOT RECRUITING Phase 1

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

NCT03278782
ACTIVE NOT RECRUITING Phase 1

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

NCT03065387
ACTIVE NOT RECRUITING Phase 2

Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery

NCT03307616
ACTIVE NOT RECRUITING Phase 3

Thoracic Epidural Analgesia or Four-Quadrant Transversus Abdominus Plane Block in Reducing Pain in Patients Undergoing Liver Surgery

NCT03214510
ACTIVE NOT RECRUITING Phase 2

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

NCT03263650
ACTIVE NOT RECRUITING NA

RCT of QPS vs General Information Sheet

NCT03287492
ACTIVE NOT RECRUITING Phase 1

18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients

NCT03168737
ACTIVE NOT RECRUITING Phase 2

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

NCT03008408
ACTIVE NOT RECRUITING Phase 2

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

NCT03202316
ACTIVE NOT RECRUITING NA

Mind-Body Intervention in Glioma Couples

NCT03244995
ACTIVE NOT RECRUITING Phase 1

Selumetinib and Olaparib in Solid Tumors

NCT03162627
ACTIVE NOT RECRUITING Phase 1

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

NCT03217747
ACTIVE NOT RECRUITING Phase 1

Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

NCT03247088
ACTIVE NOT RECRUITING Phase 2

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

NCT03181100
ACTIVE NOT RECRUITING Phase 1

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

NCT03132454
ACTIVE NOT RECRUITING Phase 1

Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss

NCT03131908
ACTIVE NOT RECRUITING NA

rTMS in Improving Neuropathy in Patients With Stage I-IV Cancer Who Have Received Oxaliplatin Chemotherapy

NCT03219502
ACTIVE NOT RECRUITING Phase 2

Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer

NCT03110978
ACTIVE NOT RECRUITING Early Phase 1

Smoking Cessation Intervention During Low Dose CT (LDCT) Screening for Lung Cancer

NCT03059940
ACTIVE NOT RECRUITING Phase 2

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

NCT03175432
ACTIVE NOT RECRUITING NA

PancFit: Multimodal Exercise During Preoperative Therapy for Pancreatic Cancer

NCT03187951
ACTIVE NOT RECRUITING Phase 2

Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer

NCT03021486
ACTIVE NOT RECRUITING Early Phase 1

Tranexamic Acid in Reducing Blood Loss in Patients With Pelvic Tumors Undergoing Hemipelvectomy Surgery

NCT03128866
ACTIVE NOT RECRUITING

Magnetic Resonance (MR) Imaging & Blood Biomarkers for Head and Neck Cancer

NCT03491176
ACTIVE NOT RECRUITING NA

Lesion Detection Assessment in the Liver: Standard vs Low Radiation Dose Using Varied Post-Processing Techniques

NCT03151564
ACTIVE NOT RECRUITING Phase 1

Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma

NCT02959463
ACTIVE NOT RECRUITING Phase 4

Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

NCT03023631
ACTIVE NOT RECRUITING NA

Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer

NCT03141437
ACTIVE NOT RECRUITING NA

Dyadic Yoga Intervention for Patient With Head and Neck Cancer Undergoing Radiotherapy and Their Family Caregivers

NCT03114501
ACTIVE NOT RECRUITING NA

Hypnosedation in Relaxing Patients Undergoing Breast Cancer Surgery

NCT03012399
ACTIVE NOT RECRUITING Early Phase 1

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

NCT02812420
← Previous Page 17 of 54 Next →

Phase Distribution

PhaseTrial count
Phase 1 748
Phase 2 971
Phase 3 96
Phase 4 28

Therapeutic Areas

Hematopoietic and Lymphoid Cell Neoplasm 44
Malignant Solid Neoplasm 42
Breast Cancer 41
Acute Myeloid Leukemia 38
Leukemia 37
Myelodysplastic Syndrome 33
Lymphoma 32
Cancer 31
Recurrent Acute Myeloid Leukemia 25
Lung Cancer 23

What is open in the M.D. Anderson Cancer Center pipeline

549 recruiting of 2,692 indexed (20% open); 1,201 completed (45%).

Phase mix: 124 late (III/IV) vs 1,719 early (I/II) (early-phase heavy).

Top condition: Hematopoietic and Lymphoid Cell Neoplasm (44 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Related

Compare saved trials side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.